| Year |
Citation |
Score |
| 2021 |
Tsutsumi E, Stricklin J, Peterson EA, Schroeder JA, Kim S. Cxcl10 chemokine induces migration of ING4-deficient breast cancer cells via a novel crosstalk mechanism between the Cxcr3 and Egfr receptors. Molecular and Cellular Biology. MCB0038221. PMID 34871062 DOI: 10.1128/MCB.00382-21 |
0.558 |
|
| 2020 |
Peng S, Hebert LL, Eschbacher JM, Kim S. Single-Cell RNA Sequencing of a Postmenopausal Normal Breast Tissue Identifies Multiple Cell Types That Contribute to Breast Cancer. Cancers. 12. PMID 33291647 DOI: 10.3390/cancers12123639 |
0.436 |
|
| 2019 |
Hendricks WPD, Briones N, Halperin RF, Facista S, Heaton PR, Mahadevan D, Kim S. PD-1-Associated Gene Expression Signature of Neoadjuvant Trastuzumab-Treated Tumors Correlates with Patient Survival in HER2-Positive Breast Cancer. Cancers. 11. PMID 31618954 DOI: 10.3390/cancers11101566 |
0.478 |
|
| 2019 |
Briones N, Facista S, Halperin R, Heaton P, Mahadevan D, Hendricks W, Kim S. Abstract 3412: Genomic signature of trastuzumab neoadjuvant therapy predictive of patient survival in HER2-positive breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3412 |
0.434 |
|
| 2019 |
Szeto E, Kim S. Abstract 3453: CXCL10 contributes to aggressive disease progression in ING4-deficient breast cancer Cancer Research. 79: 3453-3453. DOI: 10.1158/1538-7445.Am2019-3453 |
0.609 |
|
| 2016 |
Keenen MM, Kim S. Tumor suppressor ING4 inhibits estrogen receptor activity in breast cancer cells. Breast Cancer (Dove Medical Press). 8: 211-221. PMID 27895513 DOI: 10.2147/BCTT.S119691 |
0.532 |
|
| 2015 |
Kim S. New and emerging factors in tumorigenesis: an overview. Cancer Management and Research. 7: 225-39. PMID 26251629 DOI: 10.2147/Cmar.S47797 |
0.424 |
|
| 2014 |
Berger PL, Frank SB, Schulz VV, Nollet EA, Edick MJ, Holly B, Chang TT, Hostetter G, Kim S, Miranti CK. Transient induction of ING4 by Myc drives prostate epithelial cell differentiation and its disruption drives prostate tumorigenesis. Cancer Research. 74: 3357-68. PMID 24762396 DOI: 10.1158/0008-5472.Can-13-3076 |
0.348 |
|
| 2012 |
Byron SA, Min E, Thal TS, Hostetter G, Watanabe AT, Azorsa DO, Little TH, Tapia C, Kim S. Negative regulation of NF-κB by the ING4 tumor suppressor in breast cancer. Plos One. 7: e46823. PMID 23056468 DOI: 10.1371/Journal.Pone.0046823 |
0.578 |
|
| 2012 |
Berger P, Kim S, Miranti CK. Abstract C63: Understanding prostate cancer initiation and development through differentiation: Role of ING4 and Myc in prostate differentiation and cancer development Cancer Research. 72. DOI: 10.1158/1538-7445.Prca2012-C63 |
0.344 |
|
| 2011 |
Tapia C, Zlobec I, Schneider S, Kilic E, Güth U, Bubendorf L, Kim S. Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer. Human Pathology. 42: 983-90. PMID 21315418 DOI: 10.1016/J.Humpath.2010.10.012 |
0.601 |
|
| 2011 |
Dempsey KJ, Whitsett TG, Kim S. Abstract 4024: ING4 tumor suppressor binds to estrogen receptor-complex and modulates estrogen-dependent cell growth and gene expression in breast cancer Cellular and Molecular Biology. 71: 4024-4024. DOI: 10.1158/1538-7445.Am2011-4024 |
0.563 |
|
| 2011 |
Whitsett TG, Kim S. Abstract 2180: Antagonistic relationship between the tumor suppressor ING4 and estrogen signaling in breast cancer Cellular and Molecular Biology. 71: 2180-2180. DOI: 10.1158/1538-7445.Am2011-2180 |
0.565 |
|
| 2010 |
Yang D, Liu H, Goga A, Kim S, Yuneva M, Bishop JM. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proceedings of the National Academy of Sciences of the United States of America. 107: 13836-41. PMID 20643922 DOI: 10.1073/Pnas.1008366107 |
0.309 |
|
| 2010 |
Kim S, Welm AL, Bishop JM. A dominant mutant allele of the ING4 tumor suppressor found in human cancer cells exacerbates MYC-initiated mouse mammary tumorigenesis. Cancer Research. 70: 5155-62. PMID 20501848 DOI: 10.1158/0008-5472.Can-10-0425 |
0.583 |
|
| 2010 |
Raymond-Whish SL, Kim S. Abstract 1131: ING4 attenuates breast cancer cell growth in Matrigel by altering Wnt/beta-catenin signaling pathway Cancer Research. 70: 1131-1131. DOI: 10.1158/1538-7445.Am10-1131 |
0.587 |
|
| 2010 |
Dempsey K, Whitsett TG, Kim S. Abstract 1130: ING4 tumor suppressor binds to a transcription co-activator, CCAR1, and modulates estrogen-dependent cell growth and gene expression Cancer Research. 70: 1130-1130. DOI: 10.1158/1538-7445.Am10-1130 |
0.598 |
|
| 2005 |
Kim S. HuntING4 new tumor suppressors. Cell Cycle (Georgetown, Tex.). 4: 516-7. PMID 15738650 DOI: 10.4161/cc.4.4.1584 |
0.413 |
|
| 2005 |
Welm AL, Kim S, Welm BE, Bishop JM. MET and MYC cooperate in mammary tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 102: 4324-9. PMID 15738393 DOI: 10.1073/pnas.0500470102 |
0.589 |
|
| 2004 |
Kim S, Chin K, Gray JW, Bishop JM. A screen for genes that suppress loss of contact inhibition: identification of ING4 as a candidate tumor suppressor gene in human cancer. Proceedings of the National Academy of Sciences of the United States of America. 101: 16251-6. PMID 15528276 DOI: 10.1073/pnas.0407158101 |
0.535 |
|
| Show low-probability matches. |